Lipoprotein (a) and Stroke

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2000 Aug 29

PMID 10961170

Citations 21

Authors

H J Milionis

A F Winder

D P Mikhailidis

Affiliations

Soon will be listed here.

Abstract

Strokes are one of the most common causes of mortality and long term severe disability. There is evidence that lipoprotein (a) (Lp(a)) is a predictor of many forms of vascular disease, including premature coronary artery disease. Several studies have also evaluated the association between Lp(a) and ischaemic (thrombotic) stroke. Several cross sectional (and a few prospective) studies provide contradictory findings regarding Lp(a) as a predictor of ischaemic stroke. Several factors might contribute to the existing confusion--for example, small sample sizes, different ethnic groups, the influence of oestrogens in women participating in the studies, plasma storage before Lp(a) determination, statistical errors, and selection bias. This review focuses on the Lp(a) related mechanisms that might contribute to the pathogenesis of ischaemic stroke. The association between Lp(a) and other cardiovascular risk factors is discussed. Therapeutic interventions that can lower the circulating concentrations of Lp(a) and thus possibly reduce the risk of stroke are also considered.

Citing Articles

Serum lipoprotein(a) and reclassification of coronary heart disease risk; application of prediction in a cross-sectional analysis of an ongoing Iranian cohort.

Ghavami M, Abdshah A, Esteghamati S, Hafezi-Nejad N, Nakhjavani M, Esteghamati A BMC Public Health. 2023; 23(1):2402.

PMID: 38042772 PMC: 10693688. DOI: 10.1186/s12889-023-17332-w.

Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease.

Sukahri S, Mohamed Shah F, Ismail A, Koshy M, Johari B, Mohd Razali M PLoS One. 2021; 16(6):e0253298.

PMID: 34191823 PMC: 8244858. DOI: 10.1371/journal.pone.0253298.

Associations of plasma LP(a), Hcy and D-D levels with the subtype of ischemic cerebrovascular disease.

Tang Y, Geng D Medicine (Baltimore). 2019; 98(11):e14910.

PMID: 30882710 PMC: 6426500. DOI: 10.1097/MD.0000000000014910.

Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study.

Arora P, Kalra R, Callas P, Alexander K, Zakai N, Wadley V Arterioscler Thromb Vasc Biol. 2019; 39(4):810-818.

PMID: 30786745 PMC: 6511401. DOI: 10.1161/ATVBAHA.118.311857.

Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population.

deVeber G, Kirkham F, Shannon K, Brandao L, Strater R, Kenet G Haematologica. 2019; 104(8):1676-1681.

PMID: 30679327 PMC: 6669164. DOI: 10.3324/haematol.2018.211433.

References

Carlson L, Hamsten A, Asplund A . Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989; 226(4):271-6. DOI: 10.1111/j.1365-2796.1989.tb01393.x. View

Reed D . The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol. 1990; 131(4):579-88. DOI: 10.1093/oxfordjournals.aje.a115542. View

Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M . Lipoprotein(a) in the arterial wall. Eur Heart J. 1990; 11 Suppl E:174-83. DOI: 10.1093/eurheartj/11.suppl_e.174. View

Kostner G, Bihari-Varga M . Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans?. Eur Heart J. 1990; 11 Suppl E:184-9. DOI: 10.1093/eurheartj/11.suppl_e.184. View

Smith E, Cochran S . Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis. 1990; 84(2-3):173-81. DOI: 10.1016/0021-9150(90)90088-z. View

Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B . Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991; 324(17):1149-55. DOI: 10.1056/NEJM199104253241701. View

Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6):410-8. DOI: 10.1056/NEJM199908053410604. View

Hobbs H, White A . Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999; 10(3):225-36. DOI: 10.1097/00041433-199906000-00005. View

Glader C, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G . Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. Stroke. 1999; 30(10):2013-8. DOI: 10.1161/01.str.30.10.2013. View

10.

Wissler R, VESSELINOVITCH D . Atherosclerosis in nonhuman primates. Adv Vet Sci Comp Med. 1977; 21:351-420. View

11.

Wright L, Sullivan D, Muller M, Dyne M, Tattersall M, Mountford C . Elevated apolipoprotein(a) levels in cancer patients. Int J Cancer. 1989; 43(2):241-4. DOI: 10.1002/ijc.2910430212. View

12.

Iso H, Jacobs Jr D, Wentworth D, Neaton J, Cohen J . Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989; 320(14):904-10. DOI: 10.1056/NEJM198904063201405. View

13.

Rath M, Niendorf A, Reblin T, Dietel M, Krebber H, Beisiegel U . Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989; 9(5):579-92. DOI: 10.1161/01.atv.9.5.579. View

14.

Kostner G, Gavish D, Leopold B, Bolzano K, Weintraub M, Breslow J . HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989; 80(5):1313-9. DOI: 10.1161/01.cir.80.5.1313. View

15.

Delanty N, Vaughan C . Vascular effects of statins in stroke. Stroke. 1997; 28(11):2315-20. DOI: 10.1161/01.str.28.11.2315. View

16.

Cohen A, Tzourio C, Bertrand B, Chauvel C, Bousser M, Amarenco P . Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. Circulation. 1997; 96(11):3838-41. DOI: 10.1161/01.cir.96.11.3838. View

17.

Hopkins P, Wu L, Hunt S, James B, Vincent G, Williams R . Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997; 17(11):2783-92. DOI: 10.1161/01.atv.17.11.2783. View

18.

Gazzaruso C, Buscaglia P, Garzaniti A, Falcone C, Mariotti S, Savino S . Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens. 1997; 15(3):227-35. DOI: 10.1097/00004872-199715030-00003. View

19.

Catalano M, Perilli E, Carzaniga G, Colombo F, Carotta M, Andreoni S . Lp(a) in hypertensive patients. J Hum Hypertens. 1998; 12(2):83-9. DOI: 10.1038/sj.jhh.1000540. View

20.

Elkeles R, Diamond J, Poulter C, Dhanjil S, Nicolaides A, Mahmood S . Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998; 21(4):641-8. DOI: 10.2337/diacare.21.4.641. View